WithdrawnPhase 2

A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM

A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study to Evaluate the Safety, Efficacy and Tolerability of Ofirnoflast (HT-6184) and Semaglutide in Obese or Overweight Participants With Type 2 Diabetes Mellitus (T2DM)

Lead sponsor

Halia Therapeutics, Inc.

Asset

Semaglutide

GLP-1 agonist

Listed sites

Recruiting sites

Actual enrollment

Study population

Obesity / overweight, Type 2 diabetes

Eligibility highlights

•BMI 27-40•HbA1c 7.5-10.5%

Primary endpoints

•Assess glycemic control•≥5% weight-loss responders

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07172867

Org study IDHT-6184-IIO-001

Timeline

Milestones

Study first posted2025-09-15actual

Study start2026-01-06actual

Primary completion2026-01-23actual

Study completion2026-01-23actual

Last update posted2026-02-25actual

Assets

Investigational agents

Semaglutide

Who this study enrolls

Obesity / overweightType 2 diabetes

Who can enroll

Minimum age18 Years

Maximum age65 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Participant must be 18 to 65 years of age inclusive, at the time of signing the informed consent.

•Capable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

•BMI between 27 kg/m2 and 40 kg/m2.

•Stable body weight (± 5 kg) within 90 days of screening, and body weight <150 kg.

•HbA1c is 7.5-10.5% at screening.

•Established diagnosis of T2DM.

•Receiving a stable 1mg SC q1wk dose of semaglutide (Ozempic®) for ≥ 90 days prior to signing informed consent.

•Females must meet one of the following:

1. Postmenopausal (>45 years of age with amenorrhea for at least 12 months, without using exogenous hormonal contraception and with FSH ≥ 40 IU/L).

2. Surgically sterile (hysterectomy, bilateral salpingectomy; oophorectomy) for at least 6 months.

3. Using a double contraception including a barrier method (condom, diaphragm, or occlusive cap) and a highly effective method of birth control, which includes the following:

i.Established use (i.e. at least 90 days prior to signing of ICF) of combined (estrogen and progestogen) oral, intravaginal, or transdermal hormonal contraceptive associated with inhibition of ovulation

ii.Established use (i.e. at least 90 days prior to signing of ICF) of progestogen-only oral, injectable, or implantable hormonal contraceptive associated with inhibition of ovulation

iii.Established use (i.e. at least 90 days prior to signing of ICF) of an intrauterine device (IUD) or intrauterine hormone-releasing system (IUS)

iv.Bilateral tubal occlusion completed at least 90 days prior to signing of ICF d. Vasectomized partner with the appropriate post-vasectomy documentation of the absence of spermatozoa in the ejaculate. Participant must provide documentation before the first dose of ofirnoflast (study day 1).

e. Sexual abstinence, when this is in line with the preferred and usual lifestyle of the participant

•Male participants who are sexually active with a woman of childbearing potential must agree to use a double contraception including a barrier method (male condom) and a highly effective method of contraception (highly effective methods of contraception are listed above) during the study and for 30 days after the last dose of ofirnoflast/ placebo.

•In the case of WOCBP, participants must have a negative serum pregnancy test (β-human chorionic gonadotropin [β-hCG]) at screening and negative urine pregnancy tests on first day of dosing and at each study visit.

•Able to comply with the study procedures in the view of the Investigator.

Exclusion criteria

•Any prescription or over-the-counter medications intended for weight loss within 6 months of screening, excluding semaglutide.

•History of, or known hypersensitivity to, monoclonal antibody drugs or a contraindication to semaglutide (e.g. Ozempic® or Wegovy®)

•Use of other investigational drugs at the time of screening or within 30 days or 5 half-lives prior to signing of the ICF, whichever is longer, or longer if required by local regulations

•Previous or current diagnosis of Type 1 diabetes mellitus (T1DM) or current gestational diabetes.

•Diagnosis of T2DM requiring current use of insulin, repaglinide, saxagliptin, and sulfonylureas.

Note. Use of Metformin for the purposes of glycemic control is not exclusionary.

•History of diabetic ketoacidosis (within 90 days of screening), or proliferative or severe retinopathy (i.e., retinopathy requiring acute treatment).

•Previous bariatric surgery, liposuction, or planned weight loss surgery.

•Current or past diagnosis of pancreatitis

•Current or past diagnosis of severe gastroparesis

•Personal or within first-degree relative family history of medullary thyroid cancer or multiple endocrine neoplasia type 2

•Calcitonin ≥20 ng/L measured by central laboratory at screening (individuals with elevated calcitonin at initial screening may be re-screened)

•Laboratory abnormalities at screening

•Current or history of clinically significant (per Investigator's judgment) liver or biliary disease or significantly abnormal LFT at screening (see above)

•Current acute or chronic self-reported HCV and/or HBV infection

•Current or history of clinically significant renal disease (per Investigator's judgment) or eGFR<60mL/min/1.73m2

•Prior history of malignancy (including breast cancer, lymphoma, leukemia) within the past 5 years except for cervical carcinoma in situ that has been completely resected with no evidence of recurrence or metastatic disease for at least 12 months or cured basal cell carcinoma with no evidence of recurrence for at least 12 months.

•History of a major organ transplant (e.g. kidney, heart, liver, lung) or hematopoietic stem cell/ bone marrow transplant.

•History of lymphoproliferative disease or signs/ symptoms suggestive of possible lymphoproliferative disease, including splenomegaly of lymphadenopathy.

•History or current moderate to severe congestive heart failure (New York Heart Association class III or IV), or within the last 6 months, a cerebrovascular accident, myocardial infarction, unstable angina, unstable arrhythmia or any other cardiovascular condition which, in the opinion of the Investigator, would put the participant at risk by participation in the study.

•Undergone any major surgery within 8 weeks prior to study entry or will require major surgery during the study that, in the opinion of the Investigator, would pose an unacceptable risk to the participant.

•Planning elective surgery during the study duration

•Inherited or acquired thrombophilia and/ or current or history of thromboembolic events/ disease.

•Screening 12-lead ECG that demonstrates relevant abnormalities that, in the opinion of the Investigator, are clinically significant and indicate an unacceptable risk for the participant's participation in the study (e.g., QTc >450 msec or a QRS interval >120 msec). If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated two more times and the average of the three QTc or QRS values should be used to determine the participant's eligibility.

•History or evidence of any other clinically significant concomitant disorder, condition or disease that, according to the Investigator's and medical monitor's (if consulted) judgment, would pose a risk to participant safety or interfere with the study evaluation, procedures, completion or interpretation of data

•Pregnant or breast-feeding.

•Blood donation within the last month before study day 1 (first dose of ofirnoflast or placebo)

Endpoints (8)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK

Weight & body composition

Glycemic / diabetes

Weight & body composition

2 endpoints

Primary/protocol endpoint

Assess weight loss using body weight measurements

Time frame:From first dose through End of Study (up to 12 weeks per participant)

≥5% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Assess the change in body composition utilizing DEXA body scan

Time frame:From first dose through End of Study (up to 12 weeks per participant)

Total fat mass

change from baseline, improvement

Glycemic / diabetes

2 endpoints

Primary/protocol endpoint

Assess glycemic control using HbA1c (%)

Time frame:From first dose through End of Study (up to 12 weeks per participant)

threshold achievement, improvement

LOINC 4548-4

Secondary/protocol endpoint

Assess the change in HbA1c (% point)

Time frame:From first dose through End of Study (up to 12 weeks per participant)

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Safety / tolerability / PK

4 endpoints

Secondary/protocol endpoint

Assess the PK profile; AUC 0-inf, AUC 0-last, AUC tau, Cmax, tmax, t1/2, and Cl/F

Time frame:From first dose through End of Study (up to 12 weeks per participant)

descriptive

Secondary/protocol endpoint

Assess number of participants who experience Serious Adverse Events (SAEs)

Time frame:From first dose through End of Study (up to 12 weeks per participant)

Serious AEs (any)

event count, event

Secondary/protocol endpoint

Assess number of participants who experience treatment emergent adverse events (TEAEs)

Time frame:From first dose through End of Study (up to 12 weeks per participant)

Treatment-emergent AEs (any)

event count, event

Secondary/protocol endpoint

Assess number of participants who experience treatment related adverse events (TRAEs)

Time frame:From first dose through End of Study (up to 12 weeks per participant)

Treatment-emergent AEs (any)

event count, event

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.